Alto Neuroscience raises $60M (equity + credit) to help fix the “trial and error” approach to psychiatric medication

By SharpBrains | January 31, 2023

Alto Neu­ro­science bags $25M for four Phase II drugs (End­points News): Anoth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech attempt­ing to fix the “tri­al and error” sys­tem in neu­ro­science drug R&D. Alto Neu­ro­science picked up the cap­i­tal from Alpha Wave Ven­tures via an exten­sion to its Series B, bring­ing total equi­ty raised…

Read More